跳至主要内容
临床试验/NCT07574242
NCT07574242已完成不适用

Evaluation of the Effect of Vitamin K2 on the Clinical Outcome of Pediatric Patients With Atopic Dermatitis

October 6 University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年8月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
1
主要终点
to evaluate the impact of vitamin K2 on the severity of atopic dermatitis, as assessed by the SCORAD score

研究概览

简要总结

investigate the effectiveness and safety of adding vitamin K2 at a dose of 45 mg/day for 12 weeks to conventional therapy for paediatric patients with moderate to severe atopic dermatitis according to SCORAD score

详细描述

This was a multicentre, prospective, blind randomized. patients are randomized to either receive their conventional therapy alone or by adding vitamin k2 for 12 weeks. The primary outcome was to evaluate the impact of vitamin K2 on the severity of atopic dermatitis, as assessed by the SCORAD score at 12 weeks compared to baseline.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
6 Years 至 12 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •patients aged 6-12 years
  • •moderate to severe AD according to SCORAD score

排除标准

  • •other cutaneous allergic diseases (urticaria, angioedema, anaphylaxis, contact dermatitis).
  • •primary immunodeficiency (PID) with cutaneous allergic manifestations.

研究组 & 干预措施

Patients received placebo orally once daily for 12 weeks in addition to their Conv

Placebo Comparator

Patients received placebo orally once daily for 12 weeks in addition to their Conv

干预措施: Placebo (Other)

vit k2 group

Active Comparator

receive oral vitamin k2 45mg once daily for 12 weeks in addition to their conventional treatment

干预措施: vit k2 (Dietary Supplement)

结局指标

主要结局

to evaluate the impact of vitamin K2 on the severity of atopic dermatitis, as assessed by the SCORAD score

时间窗: at baseline and after 3months

次要结局

  • Janus kinase (JAK)(Measured at baseline and after three months)
  • Serum total IgE(At baseline and after three months)
  • IL-13(at baseline and after three months)
  • lipid profile(at baseline and after three months)
  • Examination of the skin for eczema distribution, extent and intensity and Complete systemic examination for different forms of allergic disorder.(3months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Aya Elsayed

Dr Aya elsayed

October 6 University

研究点 (1)

Loading locations...

相似试验